Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia

CompletedOBSERVATIONAL
Enrollment

147

Participants

Timeline

Start Date

October 23, 2020

Primary Completion Date

January 12, 2022

Study Completion Date

January 12, 2022

Conditions
Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure
Interventions
DRUG

Calcium Polystyrene Sulphonate 15g/60 mL water

K+ binder, not for treatment but for tasting (sip-and-spit taste test)

DRUG

Lokelma® 5 g/45mL water

K+ binder, not for treatment but for tasting (sip-and-spit taste test)

DRUG

Lokelma® 10 g/45 mL water

K+ binder, not for treatment but for tasting (sip-and-spit taste test)

DRUG

Veltassa® 8,4 g/80mL water

K+ binder, not for treatment but for tasting (sip-and-spit taste test)

DRUG

Sodium Polystyrene Sulphonate 15g/60 mL water

K+ binder, not for treatment but for tasting (sip-and-spit taste test)

Trial Locations (18)

8035

Research Site, Barcelona

14004

Research Site, Córdoba

15006

Research Site, A Coruña

16132

Research Site, Genova

27100

Research Site, Pavia

28031

Research Site, Madrid

33411

Research Site, West Palm Beach

33637

Research Site, Temple Terrace

80054

Research Site, Amiens

92104

Research Site, Boulogne-Billancourt

M5G 2C4

Research Site, Toronto

J4V 2H1

Research Site, Greenfield Park

H1T 2M4

Research Site, Montreal

G1L 3L5

Research Site, Québec

06000

Research Site, Nice

Unknown

Research Site, Parma

631 88

Research Site, Eskilstuna

182 88

Research Site, Stockholm

Sponsors

Lead Sponsor

Collaborators (2)

All Listed Sponsors
collaborator

Labcorp Corporation of America Holdings, Inc

INDUSTRY

collaborator

Calyx

UNKNOWN

collaborator

ERT: Clinical Trial Technology Solutions

OTHER

collaborator

Medidata Solutions

INDUSTRY

lead

AstraZeneca

INDUSTRY